Lung cancer combo study halted early after only 4 patients
NCT ID NCT05215951
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 23 times
Summary
This study tested a combination of the targeted drug osimertinib and chemotherapy as a first treatment for people with advanced non-small cell lung cancer that has uncommon EGFR mutations. The goal was to see if the combo could shrink tumors and delay cancer growth. However, the study was stopped early and only enrolled 4 participants, so results are very limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Chengdu, 610041, China
-
Research Site
Harbin, 150049, China
-
Research Site
Mianyang, 621000, China
-
Research Site
Nanchong, 637000, China
-
Research Site
Yibin, 644000, China
-
Research Site
Zhengzhou, 450000, China
Conditions
Explore the condition pages connected to this study.